Our emerging understanding of the pro-survival pathways that malignant cells maintain and the mechanisms by which nonmalignant and malignant cells respond to ionizing radiation (IR) damage have stimulated thoughtful searches for new molecular therapeutic strategies that would enhance IR. In this Molecular Cancer Therapeutics Focus, published in February 2018, Dr. John S. Lazo discusses how our emerging knowledge base is being exploited to advance the use of IR for the treatment of glioblastoma, non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and prostate cancer. Collectively, these articles highlight the frontiers of modern molecular cancer radiotherapy and are likely to help ensure that IR remains a central pillar for cancer therapy in this century.
Refining Radiation for the Next Century
Lazo JS. Molecular Cancer Therapeutics February 2018.
Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner
Palanichamy K...Chakravarti A. Molecular Cancer Therapeutics February 2018.
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma
Narayan RS…Sminia P. Molecular Cancer Therapeutics February 2018.
Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Eke I…Coleman CN. Molecular Cancer Therapeutics February 2018.
The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors
Vanderdys V…Abbas T. Molecular Cancer Therapeutics February 2018.
Radiosensitisation in vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Groselj B…Kiltie AE. Molecular Cancer Therapeutics February 2018.
Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Hinrichs CN...Kunz-Schughart LA. Molecular Cancer Therapeutics February 2018.
HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation
Efimova EV…Kron SJ. Molecular Cancer Therapeutics February 2018.
A A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers
Du J…Liu F. Molecular Cancer Therapeutics February 2018.
A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist
Morita A…Inaba T. Molecular Cancer Therapeutics February 2018.
Molecular Cancer Therapeutics Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (267) 765-1090 | E-mail: mct@aacr.org